BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38596687)

  • 1. Targeting PRAME for acute myeloid leukemia therapy.
    Yang J; Chen M; Ye J; Ma H
    Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
    Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
    Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
    Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
    J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
    Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
    Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
    Zhou PY; Li WJ; Wei CX; Zhou Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1177-81. PubMed ID: 18088461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
    Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
    Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quantification of the PRAME transcripts in patients with acute myeloid leukemia].
    Zhu ZH; Qian J; Lin J; Yao DM; Qian Z; Wang YL; Chen Q; Han LX; Xiao G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):149-52. PubMed ID: 20376794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of PRAME gene in acute leukemia and its clinical significance].
    Zhu YL; Liu J; Zhu P; DU JW; Zhang Y; Gu JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1144-9. PubMed ID: 18088454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.
    Steinbach D; Hermann J; Viehmann S; Zintl F; Gruhn B
    Cancer Genet Cytogenet; 2002 Mar; 133(2):118-23. PubMed ID: 11943337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.
    Abdelmalak CA; Yahya RS; Elghannam DM; El-Khadragy AE; Abd El Messih HM
    Clin Lab; 2014; 60(1):55-61. PubMed ID: 24600975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.